Skip to content

Psychedelics and Psychotherapy: Is the Whole Greater than the Sum of its Parts?

Robert H. Dworkin, Michael P McDermott, Sandeep M. Nayak, Eric C. Strain

Clinical Pharmacology & Therapeutics October 5, 2023 DOI: 10.1002/cpt.3050 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Commentary Peer reviewed
Topics Anxiety Mescaline Psilocybin
Keywords Psychotherapist Clinical trial Hallucinogen Clinical psychology
Citations 16
Key points Argues that because most psychedelic trials combine a psychedelic with psychotherapy-like support, and psychotherapy is costlier and harder to scale than harm-reduction support alone, factorial-design trials are needed to isolate the effects of the psychedelic, the psychotherapy, and their interaction, thereby informing safe and cost-effective treatment development.

Abstract

Clinical trials of psychedelics have provided support for their potential efficacy and safety.Although most combined a psychedelic with psychological support akin to psychotherapy, providing psychotherapy is costlier and more difficult to scale than providing only support to reduce harms.Trials with factorial designs can evaluate the individual effects of a psychedelic and psychotherapy and any synergistic interaction between them.Such trials would provide an important evidence base for developing safe and cost-effective psychedelic treatments.

Citations in the library

Explore topics

By condition and practice